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Abstract
Background: MUC1 and MUC3 are from a large family of glycoproteins with an aberrant
expression profile in various malignancies. Much interest has been focused on the role of these
proteins in the development and progression of colorectal cancer; however, no previous studies
have included the highly confounding variable of vascular invasion in their survival analysis. Using
high throughput tissue microarray technology we assessed the prognostic value of MUC1 and
MUC3 expression in the largest cohort of colorectal cancer patients to date. We propose that
tumours lacking expression of MUC1 and MUC3 will be more likely to metastasise, due to
previously observed loss of cell-cell adhesion, and this will therefore lead to more aggressive
cancers with poorer prognosis.
Methods: A tissue micro-array was prepared from tumour samples of 462 consecutive patients
undergoing resection of a primary colorectal cancer. A comprehensive prospectively recorded data
base with mean follow up of 75 months was collected and included common clinicopathological
variables and disease specific survival. Immunohistochemical analysis of MUC1 and MUC3
expression was performed using antibodies NCL-MUC1 and 1143/B7 respectively, results were
correlated with the variables within the database.
Results: Positive expression of MUC1 and MUC3 was seen in 32% and 74% of tumours
respectively. On univariate analysis no correlation was seen with either MUC1 or MUC3 and any
of the clinicopathological variables including tumour grade and stage, vascular invasion and tumour
type. Kaplan-Meier analysis demonstrated a significant reduction in disease specific survival with
MUC1 positive tumours (p = 0.038), this was not seen with MUC3 (p = 0.552). On multivariate
analysis, using Cox proportional hazards model, MUC1 expression was shown to be an
independent marker of prognosis (HR 1.339, 95%CI 1.002–1.790, p = 0.048).
Conclusion: MUC1 expression in colorectal cancer is an independent marker of poor prognosis,
even when vascular invasion is included in the analysis. These results support previous studies
suggesting a role for MUC1 in colorectal cancer development possibly through its effects on cell
adhesion.
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Colorectal cancer is the second most common cause of
cancer related death in the developed world [1], in conse-
quence advances in our understanding and treatment of
colorectal cancers can potentially have a huge impact on
cancer morbidity and mortality. Currently much of our
understanding of cancer behaviour, including the predic-
tion of likely patient outcomes, is based on histopatho-
logical parameters, and from this treatment is tailored to
individual patients. At present TNM stage, tumour type
and resection margin status are the most widely used
parameters in planning adjuvant treatment. Tumour
grade of differentiation, vascular invasion and more
recently perineural invasion and tumour border configu-
ration have also been used to assist the clinician in pre-
dicting colorectal tumour behaviour and hence
subsequent patient management [2].
It is well recognised that clinical response and recurrence
rates vary within the conventionally staged groups and
that this reflects variation in the genetic and molecular
make-up of these tumours. Molecular changes occur
within cancer cells during tumour progression; these
changes provide a potential insight into tumour develop-
ment and metastasis.
Refining prognostic markers allow treatment to be more
accurately tailored to individual patients, as well as sug-
gesting potential mechanisms through which tumour pro-
gression occurs which in turn could provide targets for
novel therapies.
MUC1 is a membrane bound glycoprotein which has
been demonstrated to be predictive of tumour progres-
sion and worsening prognosis in both gastric [3-5] and
colorectal cancer [6,7] including those related to HNPCC
[8]. This increased expression has been seen more pre-
dominantly at the invasive tumour front [9].
MUC3 is also a trans-membrane glycoprotein which is
seen in both colorectal cancers and normal colon [10].
Studies have shown an association between MUC3
expression and poor prognosis in a number of cancers
including pancreatic [11], breast [12], gastric [13] and
renal [14]. There is some evidence suggesting that MUC3
expression is reduced in colorectal cancers and that this
varies between histological types [15]. The cellular distri-
bution is also seen to be affected; apolar distribution is
thought to reflect abnormal transport systems [16].
Whilst previous studies have suggested that tumour
expression of MUC1 may be a useful prognostic factor in
colorectal carcinoma [6,9] these studies have failed to
include the presence or absence of vascular invasion in
their analysis, this is known to be a highly significant
prognostic factor in colorectal cancer[17]. We assessed the
prognostic value of MUC1 on a larger set of colorectal
tumours and included vascular invasion in our analysis to
determine if MUC1 was truly independent as the previous
studies have suggested. We also wanted to assess whether
MUC3 demonstrated any prognostic influence on color-
ectal cancers as seen in other tumours.
Since its first description in 1998, tissue micro-array
(TMA) analysis [18] has been employed for the immuno-
histochemical analysis of target protein expression in a
wide range of primary tumour types. Initial fears that the
reduced amount of individual tumour tissue analysed
using this technique might not be representative of the
tumour as a whole appear largely unfounded [19]. The
strengths of this approach lie in its ability to provide a
rapid turnover of results from very large patient cohorts,
whilst reducing variability in experimental conditions and
reducing costs [20]. Recently, in an attempt to overcome
some of the reporting deficiencies inherent in prognostic
tumour marker studies a set of guidelines, the reporting
recommendations for tumour Marker prognostic studies
(REMARK) have been proposed [21]. The reporting of this
study therefore adheres to the REMARK guidelines. This
TMA of colorectal cancer patients has previously been val-
idated with a p53(-)/Bcl-2(+) phenotype, loss of HLA or
over-expression of MICA all being independent markers
of poor survival [22-24]. TMAs have also been utilised
with MUC1 and MUC3 expression in breast cancer [12].
We have therefore used TMA technology to analyze
expression of MUC1 and MUC3 in a series of 462 paraffin
embedded colorectal tumour specimens, in conjunction
with a detailed data base of clinicopathological variables
including disease specific survival. We propose that
tumours lacking expression of MUC1 and MUC3 will be
more likely to metastasise, due to previously observed loss
of cell-cell adhesion, and this will therefore lead to more
aggressive cancers with poorer prognosis.
Methods
Patients and study design
The study population comprised a series of 462 consecu-
tive patients undergoing elective surgical resection of a
histologically proven sporadic primary colorectal cancer
at the University Hospital, Nottingham, UK (table 1).
These patients were treated between 1st January 1994 and
31st December 2000; this time period allowed meaning-
ful assessment of the prognostic markers studied. All
patients treated during this time-frame were considered
eligible for inclusion in the study. Tumours were classified
as mucinous carcinoma, when more than 50% of tumour
volume consisted of mucin [25].Page 2 of 11
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unavailable were excluded from the study. Follow-up was
calculated from time of resection of the original tumour
with all surviving cases being censored for data analysis at
31st December 2003, this produced a median follow up
of 37 months (range 0–116) for all patients and 75
months (range 36–116) for survivors.
A prospectively maintained database was used to record
relevant clinicopathological data, with data provided
from the UK Office for National Statistics; this was availa-
ble in more than 99% of cases. The information collected
was independently validated through case note review of
deceased patients. Disease specific survival was used as the
primary end point; however, data was also collected on
the various other relevant clinical and histopathological
parameters these are summarised in table 1. There was no
formal sample size calculation performed, although the
inclusion of over 450 cases is in excess of most studies of
prognostic tumour markers.
Adjuvant chemotherapy consisting of 5 FU and folinic
acid was reserved for those patients with positive lymph
nodes, although, surgical and adjuvant treatment was at
the discretion of the supervising physician.
Prior ethical review of the study was conducted by the
Nottingham Local Research and Ethics Committee, who
granted approval for the study.
Construction of the array blocks incorporated a wide spec-
trum of electively resected colorectal tumours and was
found to be broadly representative of the colorectal cancer
population in the UK. 266 (58%) patients were male and
196 (42%) female. The median age at the time of surgery
was 72 years, consistent with a median age at diagnosis of
colorectal cancer of 70–74 years in the UK [26]. 69 (15%)
tumours arrayed were TNM stage 1, 174 (38%) stage 2,
155 (34%) stage 3 and 54 (11%) stage 4; there were 3
cases of in-situ disease. These figures are comparable with
national figures for distribution of stage 1–4 at diagnosis
of 11, 35, 26 and 29% respectively [27]. The majority of
tumours (392, 85%) were adenocarcinomas, and were
most frequently of a moderate histological grade (353,
77%). 128 (28%) tumours were noted to have histologi-
cal evidence of extramural vascular invasion, 224 (48%)
had no evidence of vascular invasion, and this informa-
tion was not available in 110 (24%) cases.
At the time of censoring for data analysis 228 (49%)
patients had died from their disease, 64 (14%) were
deceased from all other causes, and 169 (37%) were alive.
The median five-year disease-specific survival for the
cohort was 58 months, comparable with a national aver-
age of approximately 45% five-year survival for colorectal
cancer in the UK [27].
Specimen characteristics
All tumours received following resection in the operating
theatre were incised, fixed immediately in 10% neutral
buffered formalin followed by standard processing
through to embedding in paraffin wax, ensuring optimal
tissue fixation and preservation for histological examina-
tion.
Tissue micro-arrays were constructed as described previ-
ously [18]. For each tumour, 5 µm section slides stained
with haematoxylin-eosin were first used to locate repre-
sentative areas of viable tumour tissue. 0.6 mm needle
core-biopsies from the corresponding areas on the paraf-
fin-embedded tumour blocks were then placed at pre-
specified coordinates in recipient paraffin array blocks
using a manual tissue-arrayer (Beecher Instruments, Sun
Table 1: Clinico-pathological variables for the patient cohort (n = 
462)
Gender Male 266 (58%)
Female 196 (42%)
Age (years) Median 72
Range 57–89
Status Alive 169 (37%)
Dead (colorectal related) 228 (49%)
Dead (non-colorectal related) 64 (14%)
Unknown 1
Tumour Grade Well differentiated 29 (6%)
Moderately differentiated 353 (77%)
Poorly differentiated 71 (15%)
Unknown 8 (2%)
Tumour Site Colon 238 (52%)
Rectum 181 (39%)
Unknown 43 (9%)











Histological type Adenocarcinoma 392 (85%)
Mucinous carcinoma 51 (11%)
Columnar carcinoma 4 (1%)
Signet ring carcinoma 7 (1%)
Unknown 8 (2%)Page 3 of 11
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80–150 cores in each, with analysis of a single core from
each case. Fresh 5 µm sections were obtained from each
TMA block and placed on coated glass slides to allow the
immunohistochemical procedures to be performed, pre-
serving maximum tissue antigenicity.
Immunohistochemistry
Immunohistochemical analysis of MUC1 and MUC3
expression was performed using a routine streptavidin-
biotin peroxidase method. Tissue array sections were first
deparaffinised with xylene, rehydrated through graded
alcohol and immersed in methanol containing 0.3%
hydrogen peroxide for 20 minutes to block endogenous
peroxidase activity. In order to retrieve antigenicity, sec-
tions were immersed in 500 mls of pH 9.0 EDTA buffer
and heated for 10 min in an 800 W microwave at high
power, followed by 10 min at low power. Endogenous
avidin/biotin binding was blocked using an avidin/biotin
blocking kit (Vector Labs, USA). In order to block non-
specific binding of the primary antibody all sections were
then treated with 100 µl of 1/5 normal swine serum (NSS)
in TBS for 15 min.
Test sections were incubated with 100 µl of mouse mono-
clonal antibodies recognising MUC 1 (NCL-MUC1 Novo-
castra, Newcastle, UK) which was found to show optimal
staining at a dilution of 1/200 (v/v) in NSS/TBS, or MUC
3 (MUC3 1143/B7 NeoMarkers, California, USA) at 1/75
(v/v) NSS/TBS for 60 min at room temperature. Positive
control tissue comprised whole sections of breast cancer
tissue. The primary antibody was omitted from the nega-
tive control, which was left incubating in NSS.
After washing with TBS, all sections were incubated with
100 µl of biotinylated goat anti-mouse/rabbit immu-
noglobulin (Dako Ltd, Ely, UK) diluted 1:100 in NSS, for
30 min. Sections were washed again in TBS and next incu-
bated with 100 µl of pre-formed streptavidin-biotin/
horseradish peroxidase (HRP) complex (Dako Ltd, Ely,
UK) for 60 min at room temperature. Subsequently, visu-
alisation of MUC 1/MUC3 expression was achieved using
3, 3'-Diaminobenzidine tetra hydrochloride (DAB, Dako
Ltd, Ely, UK). Finally, sections were lightly counterstained
with haematoxylin (Dako Ltd, Ely, UK), dehydrated in
alcohol, cleared in xylene (Genta Medica, York, UK) and
mounted with distyrene, plasticiser and xylene (DPX –
BDH, Poole, UK).
Evaluation of MUC1 and MUC3 staining
The tumour cores were assessed by two observers (TJD
and AHA) with regard to distribution and intensity of
staining, both with extensive experience in the analysis of
tissue micro-arrays. Tumours were classified according to
a semi-quantitative system in a coded manner and
blinded to the clinical and pathological parameters of the
case. In the few cases (<5%) where there was discrepancy
between the classification of cores a review, using a dou-
ble headed microscope, was performed and a consensus
reached.
For MUC1, tumours were scored according to the propor-
tion of viable tumour cells within the tumour core which
displayed unequivocal staining and scored: None = 0,
<5% = 1, 5–29% = 2, 30–59% = 3, >60% = 4 in line with
previous studies using the same antibody [6,28]. As the
expression of MUC 3 was more uniform throughout pos-
itive tumour cores the intensity of staining was used as the
discriminator with tumours categorised as showing nega-
tive, low, moderate and high intensity of MUC3 expres-
sion. For the purposes of survival analysis tumours were
further categorised as either negative or positive for
marker expression. Tumours were considered positive for
MUC 1 expression when at least 30% of cells demon-
strated positive staining, this is in keeping with previous
studies [6,28]. For MUC3 tumours displaying moderate or
high intensity staining were considered positive, with the
remainder considered negative
Statistical analysis
Statistical analysis of the study data was performed using
the SPSS package (version 14 for Windows, SPSS Inc., Chi-
cago, IL). Pearson χ2 chi-square tests were used to deter-
mine the significance of associations between categorical
variables. Disease-specific survival calculations included
all patients whose death related to colorectal cancer. In
contrast, patients whose deaths resulted from non-color-
ectal cancer related causes were censored at the time of
death. Kaplan-Meier curves were used to assess factors
which influenced survival. The statistical significance of
differences in disease-specific survival between groups
with differing MUC1 and MUC3 expression was esti-
mated using the log-rank test. The Cox proportional-haz-
ards model was used for multivariate analysis in order to
determine the relative risk and independent significance
of individual factors. In all cases p-values < 0.05 were con-
sidered as statistically significant.
Results
Patient and histopathological variables and prognosis
Univariate relationships between known patient/tumour
characteristics and DSS were evaluated using the log-rank
test (see Table 2). There appeared to be no significant dif-
ferences in DSS between patients of either gender. Simi-
larly when patient age was considered in three groups
(patients 64 years or younger at the time of surgery,
patients 65–79 years, and those 80 years and over), no sig-
nificant differences in DSS were noted. The site of tumour
i.e. colon or rectum had no influence on DSS.Page 4 of 11
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with increasing dedifferentiation, with colorectal cancer
related deaths occurring in 34.5% (10/29), 48.4% (171/
353) and 56.3% (40/71) of patients with well, moderately
and poorly differentiated tumours respectively, although
this did not reach statistical significance in our cohort of
patients. The majority of tumours were adenocarcinomas,
however non-adenocarcinoma tumours, did not have a
statistically significantly poorer prognosis in this series.
Extramural vascular invasion had a strong correlation
with survival, 72% (92/128) of patients with evidence of
vascular invasion died from colorectal cancer related
causes, compared with only 39% (87/224) in patients
without. In cases where the vascular invasion status was
unknown an intermediate mean DSS was noted. The asso-
ciation between vascular invasion and DSS was highly sig-
nificant and log-rank testing (log-rank = 44.30, p <
0.0001).
The strongest association of clinicopathological variables
with DSS was seen with TNM staging (log-rank = 211.37,




Analysis of MUC1 expression was possible in 403 of the
462 tumours on the TMA (87%), with the remainder
being lost during antigen retrieval or not demonstrating
viable tumour cells within the core. This level of core loss
is within the rates described by previous authors using
TMAs [29,30]. The majority of staining was seen within
Table 2: Univariate survival analysis of patient/tumour characteristics
Variable Total Number (%) Mean DSS (months) 95% CI (months) log rank p value
Gender
Male 266 (57) 64 57–70
Female 196 (42) 64 57–71 0.8374
Age (years)
<64 71 (15) 66 54–77
65–79 316 (68) 64 58–69
80+ 75 (16) 61 49–72 0.9602
Tumour Grade
Well 29 (6) 66 45–86
Moderate 353 (76) 65 60–71
Poor 71 (15) 57 46–69
Unknown 9 (2) 52 7–37 0.0627
Tumour Site
Colon 238 (52) 66 59–72
Rectum 181 (39) 65 58–73
Unknown 43 (9) 46 31–60 0.0620
TNM Stage
0/I 72 (15) 98 89–106
II 174 (38) 79 71–86
III 155 (33) 52 44–59
IV 54 (12) 8 6–10
Unknown 7 (2) 29 8–50 <0.0001
Vascular Invasion 
Status
Absent 224 (48) 75 68–81
Present 128 (28) 38 31–45
Unknown 110 (24) 68 59–78 <0.0001
Tumour type
Adenocarcinoma 392 (84) 65 60–70
Mucinous 51 (11) 66 52–79
Columnar 4 (1) 51 8–94
Signet ring 7 (2) 27 11–44 0.4860
MUC1 expression
High 127 (32) 54 45–62
Low 276 (68) 65 60–71 0.038
MUC3 expression
High 286 (74) 63 57–69
Low 101 (26) 59 49–69 0.552Page 5 of 11
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within the nucleus or surrounding stromal tissue. No
staining was seen in 188 (47%) tumours, with <5% and
5–30% of cells staining in 47 (12%) and 41 (10%) respec-
tively. There was 30–60% staining in 62 (15%) cores and
greater than 60% in 65 (16%). When dividing the
tumours according to previous studies [6,28] 276 (68%)
tumours were MUC1 negative and 127 (32%) positive.
MUC3
Analysis of MUC3 expression was possible in 387 cores
(84%). The staining was seen mainly within the cyto-
plasm 354 (91%) but also with the cell membrane 147
(38%), there was no nuclear staining but occasional stro-
mal staining seen. The majority of tumours displayed
either moderate 187 (48%) or strong staining 99 (26%),
weak or no staining was seen in 68 (18%) and 33 (8%)
respectively.
Representative examples of positive and negative staining
for each antigen are shown in figure 1.
Relationships between tumour markers and standard 
clinicopathological variables
MUC1
For the purposes of analysis the tumours were divided
into those with positive or negative expression, as
described previously [6,28]. There did not appear to be
Immunohistochemical staining of tissue microarray cores with MUC1 and MUC3 antibodiesFigure 1
Immunohistochemical staining of tissue microarray cores with MUC1 and MUC3 antibodies. A & B show cores 
from tumour demonstrating positive (A) and negative (B) MUC1 staining. C & D show cores of tumour demonstrating strong 
(C) and weak MUC 3 staining. All are at × 100 magnification.Page 6 of 11
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variables, including stage, and MUC1 expression (see
table 3).
MUC3
As the majority of tumour cells within each core expressed
a uniform staining pattern, the cores were classified
according to intensity of staining as opposed to the pro-
portion of cells staining. Cores were deemed positive if
moderate or strong staining was seen. Using this system
286 (74%) tumours were positive and 101 (26%) nega-
tive. No correlation between MUC3 cytoplasmic expres-
sion and any clinicopathological variables, including
stage, was seen (see table 4). Equally there was no correla-
tion of membranous staining with any clinicopathologi-
cal variables (data not shown).
Relationship between tumour markers and patient survival
Correlation between MUC1 and MUC3 expression and
DSS was assessed using Kaplan-Meier plots and log rank
testing (see table 2, figures 2 and 3). A significant associa-
tion was seen between tumours with high MUC1 expres-
sion and a reduced DSS (mean DSS 54 months vs. 65
months; p = 0.038). In contrast, there was no correlation
between MUC3 expression and DSS.
In order to determine the relative influence of MUC1 and
other patient and tumour variables known to affect prog-
nosis, a multivariate analysis was performed using the
Cox proportional hazards model. We included only those
variables which had been shown to be significantly
related to DSS on univariate analysis i.e. intramural vascu-
lar invasion and TNM stage (see table 5). In this model,
vascular invasion (p < 0.001) and TNM staging (p <
0.001) were seen to retain independent prognostic signif-
icance. High expression of MUC1 was also seen to be an
independent prognostic marker of poor outcome, with a
hazard ratio of 1.339 (95%CI 1.002–1.790, p = 0.048),
when compared with tumour demonstrating low MUC1
expression.
Discussion
This study investigates the role of MUC1 and MUC3 as
prognostic markers in colorectal cancer. Previous studies
have suggested a link between MUC1 and MUC3 expres-
sion and poor prognosis both in colorectal and other
tumour types [3-8]. These studies have frequently suffered
from small sample sizes and/or heterogeneous methodol-
ogy and study populations. The current study comprises
the largest analysis of MUC1 and MUC3 expression in
colorectal cancer to date; including 463 consecutively
Table 3: Patient and Tumour characteristics in relation to MUC1 expression (n = 403)
Variable Total Number Number (%) MUC1 + Number (%) MUC1 - χ2 test (p value)
Gender
Male 227 73 (32) 154 (68)
Female 176 54 (31) 122 (69) 0.418
Tumour Grade
Well 27 11 (41) 16 (59)
Moderate 302 94 (31) 208 (69)
Poor 65 18 (28) 47 (72)
Unknown 9 4 (44) 5 (56) 0.527
Tumour Type
Adenocarcinoma 344 111 (32) 233 (68)
Mucinous 42 10 (24) 32 (76)
Other 9 2 (22) 7 (78)
Unknown 8 4 (50) 4 (50) 0.412
Tumour Site
Colon 211 69 (33) 142 (67)
Rectum 155 43 (28) 112 (72)
Unknown 37 15 (40) 22 (60) 0.279
TNM Stage
0 3 0 3 (100)
I 59 19 (32) 40 (68)
II 152 44 (29) 108 (71)
III 134 43 (32) 91 (68)
IV 48 17 (35) 31 (65)
Unknown 7 4 (57) 3 (43) 0.501
Vascular Invasion 
Status
Positive 116 38 (33) 78 (67)
Negative 193 67 (35) 176 (65)
Unknown 94 22 (23) 72 (77) 0.145Page 7 of 11
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the colorectal cancer population within the UK. With a
comprehensive data set of clinicopathological variables
and patient outcome, over a median 3 year postoperative
period, a thorough and comprehensive analysis was pos-
sible between these variables and disease specific survival.
In our study population 32% of tumours were positive for
MUC1. This compares favourably with previous authors
work, who also used the same semi-quantitative scoring
system and found 32% and 43% MUC1 positivity in
colorectal tumours respectively[6,28].
In our study population MUC1 expression was not related
to any of the clinicopathological variables examined.
Some previous studies demonstrated increased MUC1
expression was related to increasing TNM or Dukes stage
[31-33]; however, a number of other studies are in line
with our findings [9,34]. Variations in the findings of the
current and previous studies may relate to differences in
immunohistochemical protocols, antibodies used, scor-
ing systems and area of the tumour examined e.g. Hiraga
et al and Kimura et al only assessed staining at the invasion
front [31,32]. A large study by Lugli et al examines the
prognostic significance of MUC1 and MUC2 in relation to
differing mismatch repair status in colorectal cancer, with
tumours divided into three subgroups. Significant correla-
tions were found in the "mismatch repair proficient
group" between MUC1 positivity and tumour stage and
grade [33]. There was no such correlation in our cohort,
however our analysis did not involve sub-stratification of
the population and hence may explain the dissimilar
results.
Univariate and multivariate analysis of our patient popu-
lation confirmed that TNM staging and vascular invasion
are strong independent prognostic markers in colorectal
cancer. Of particular interest was the large effect vascular
invasion had on survival. Presence of vascular invasion
reduced mean DSS significantly (38 vs 75 months p <
0.0001), yet no previous studies investigating the prog-
nostic value of MUC1 have included this obviously strong
predictor of survival in their analysis. Our data confirm
that high expression of MUC1 in colorectal cancer confers
Table 4: Patient and Tumour characteristics in relation to MUC3 expression (n = 387)
Variable Total Number Number (%) MUC3 + Number (%) MUC3 - χ2 test (p value)
Gender
Male 221 167 (76) 54 (24)
Female 166 119 (72) 47 (28) 0.390
Tumour Grade
Well 22 20 (91) 2 (9)
Moderate 295 227 (77) 68 (23)
Poor 61 31 (50) 30 (50)
Unknown 9 8 (89) 1 (11) 0.389
Tumour Type
Adenocarcinoma 326 245 (75) 81 (25)
Mucinous 43 30 (70) 13 (30)
Other 10 4 (40) 6 (60)
Unknown 8 7 (87) 1 (13) 0.061
Tumour Site
Colon 201 142 (71) 59 (29)
Rectum 153 116 (76) 37 (24)
Unknown 33 28 (85) 5 (15) 0.160
TNM Stage
0 3 2 (67) 1 (33)
I 58 47 (81) 11 (19)
II 146 112 (77) 34 (23)
III 128 89 (70) 39 (30)
IV 45 30 (67) 15 (33)
Unknown 7 6 (86) 1 (14) 0.391
Vascular Invasion 
Status
Positive 106 78 (73) 28 (27)
Negative 194 149 (77) 45 (23)
Unknown 87 59 (23) 28 (32) 0.283Page 8 of 11
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analysis, even when taking into account the potentially
confounding influence of vascular invasion status.
The association of MUC1 with poor prognosis has been
linked to effects on cell adhesion and the potential for
metastasis. Regimbald et al [35] showed that MUC1 was a
ligand for ICAM-1 in breast cancer and might have a piv-
otal role in haematogenous spread, and it has been spec-
ulated that this mechanism may occur in colorectal cancer
[36]. MUC1 is also seen to have effects on the extra cellu-
lar matrix components through inhibition of kalinin and
laminin [37,38].
MUC1 has been demonstrated to affect beta-catenin, a
nuclear transcription factor, and its intracellular distribu-
tion has been shown to influence progression of colorec-
tal cancer [39], it has been suggested that MUC1 exerts
some of it's effects through interaction with beta-catenin,
with over expression of MUC1 leading to increased levels
of nuclear beta-catenin [40]. A recent study has shown
that the co-expression of MUC1 and nuclear beta-catenin
at the invasion front of colorectal tumours may be corre-
lated with a worse prognosis [9].
Table 5: Cox multivariate regression analysis of variables in relation to disease specific survival
Variable Hazard Ratio 95% CI p value
TNM Stage
0–II 1




Unknown 1.392 0.914–1.933 <0.001
MUC1 expression
Low 1
High 1.339 1.002–1.790 0.048
Kaplan-Meier plot for disease specific survival, MUC1 (+) vs. MUC1 (-) tumours (n = 403)Figure 2
Kaplan-Meier plot for disease specific survival, MUC1 (+) vs. 
MUC1 (-) tumours (n = 403).
Kaplan-Meier plot for disease specific survival, MUC3 (+) vs. MUC3 (-) tumours (n = 387)Figure 3
Kaplan-Meier plot for disease specific survival, MUC3 (+) vs. 
MUC3 (-) tumours (n = 387).Page 9 of 11
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in 76% of tumours assessed. Some studies have suggested
that MUC3 may in fact be down-regulated in colorectal
cancer compared with normal colon [10,15]. We did not
see any correlation between the clinicopathological varia-
bles and MUC3; in particular there was no correlation
with tumour stage as is seen with gastric cancers [13]. Fur-
thermore, MUC3 expression did not appear to correlate
with prognosis, as has been reported in other tumour
types [11-14]. Rakha et al demonstrated MUC3 expression
in 91% of breast cancers which was associated with
increased local recurrence and lymph node stage. They
argued that membranous expression of MUC3 was a poor
prognostic feature, which correlated with higher grade
and poorer Nottingham Prognostic Index (NPI) [12].
Wang reported that increased MUC3 expression in gastric
cancer worsened prognosis, with no significant differ-
ences in expression seen in relation to patient sex, tumour
location, grade of differentiation, serosal invasion, or Lau-
ren's type. However MUC3 expression was higher in those
with metastasis (p < 0.01) and in clinical stage III–IV dis-
ease compared to I–II (p < 0.05). MUC3 were not detected
in the normal gastric mucosa [13]. MUC3 showed a pro-
gressive increase in expression with pancreatic intraepi-
thelial neoplasia of increasing dysplasia and was also
highly expressed in ductal adenocarcinoma [11].
Normal lung tissues exhibited a distinct pattern of mucin
gene expression, with high levels of MUC1 and low levels
of MUC3 immunoreactivity and mRNA. In contrast, lung
adenocarcinomas, especially well-differentiated cancers,
exhibited increased MUC1 and MUC3 mRNA levels [41].
Copin et al found that coexpression of MUC3 and MUC1
was constant among lung adenocarcinomas [42].
Conclusion
We have demonstrated that using TMA technology and a
large cohort of colorectal cancer patients with robust long
term follow up data that biomarkers of prognosis can be
reliably assessed. Our data clearly demonstrates a role for
MUC1 in the progression of colorectal cancer, probably
through its effects on cell adhesion and metastasis. MUC1
expression appears to function as an independent prog-
nostic marker in colorectal cancer even when the conven-
tional variables of tumour stage and vascular invasion
status are included in the analysis.
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